PFO
MRTX

Pathstone Family Office’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pathstone Family Office’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$2K – 1406
2020
Q4 		$2K Buy
+7
New +$1.51K ﹤0.01% 1059
2020
Q3 		– Sell
-100
Closed -$11K – 1030
2020
Q2 		$11K Buy
+100
New +$9.7K ﹤0.01% 508

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pathstone Family Office's MRTX Position: Q1 2021 in Review

Pathstone Family Office sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 7 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in MRTX in Q2 2020 and held it in 2 quarters. The position peaked at $11K in Q2 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Pathstone Family Office reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 7 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2K.
  • Pathstone Family Office first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Pathstone Family Office's Mirati Therapeutics, Inc. Common Stock position peaked at $11K in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.